UY26718A1 - Uso de compuestos de 1-amino-5-fenilpentano-3-ol y/o 1-amino-6-fenilhexano-3-ol para la preparación de un medicamento con efecto antagonista de n-metil-d-aspartato- (nmda) - Google Patents

Uso de compuestos de 1-amino-5-fenilpentano-3-ol y/o 1-amino-6-fenilhexano-3-ol para la preparación de un medicamento con efecto antagonista de n-metil-d-aspartato- (nmda)

Info

Publication number
UY26718A1
UY26718A1 UY26718A UY26718A UY26718A1 UY 26718 A1 UY26718 A1 UY 26718A1 UY 26718 A UY26718 A UY 26718A UY 26718 A UY26718 A UY 26718A UY 26718 A1 UY26718 A1 UY 26718A1
Authority
UY
Uruguay
Prior art keywords
amino
phenylhexane
phenylpentane
nmda
aspartate
Prior art date
Application number
UY26718A
Other languages
English (en)
Inventor
Dr Bernd Sundermann
Dr Boris Chizh
Dr Werner Englerber
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of UY26718A1 publication Critical patent/UY26718A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere al uso de al menos un compuesto de 1-amino-5-fenilpentano-3-ol y/o 1-amino-6-fenilhexano-3-ol y/o uno de sus enantiómeros y/o uno de sus diastereómeros y/o una de sus sales fisiológicamente tolerables para la preparación de un medicamento con efecto antagonista de N-metil-D-aspartato- (NMDA).
UY26718A 2000-05-22 2001-05-18 Uso de compuestos de 1-amino-5-fenilpentano-3-ol y/o 1-amino-6-fenilhexano-3-ol para la preparación de un medicamento con efecto antagonista de n-metil-d-aspartato- (nmda) UY26718A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10025238A DE10025238A1 (de) 2000-05-22 2000-05-22 Verwendung substituierter 1-Amino-5-phenylpentan-3-ol- und/oder 1-Amino-6-phenylhexan-3-ol- Verbindungen als Arzneimittel

Publications (1)

Publication Number Publication Date
UY26718A1 true UY26718A1 (es) 2001-06-29

Family

ID=7643080

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26718A UY26718A1 (es) 2000-05-22 2001-05-18 Uso de compuestos de 1-amino-5-fenilpentano-3-ol y/o 1-amino-6-fenilhexano-3-ol para la preparación de un medicamento con efecto antagonista de n-metil-d-aspartato- (nmda)

Country Status (16)

Country Link
US (1) US6784175B2 (es)
EP (1) EP1289514B1 (es)
JP (1) JP2004509842A (es)
AR (1) AR029091A1 (es)
AT (1) ATE281158T1 (es)
AU (2) AU7402201A (es)
CA (1) CA2406198A1 (es)
DE (2) DE10025238A1 (es)
ES (1) ES2231502T3 (es)
HU (1) HUP0301884A2 (es)
MX (1) MXPA02011410A (es)
NZ (1) NZ521439A (es)
PE (1) PE20011261A1 (es)
PT (1) PT1289514E (es)
UY (1) UY26718A1 (es)
WO (1) WO2001089505A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6856700B1 (en) * 2000-05-24 2005-02-15 Microsoft Corporation Palettized image compression
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
KR101271263B1 (ko) * 2005-09-28 2013-06-07 아우리스 메디칼 아게 내이 장애 치료용 약학 조성물
WO2012009258A2 (en) * 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
CA2849085C (en) 2011-12-12 2019-10-01 Auris Medical Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155935A (en) * 1973-03-26 1979-05-22 American Home Products Corporation Benzylamine analgesics
US4017637A (en) 1973-03-26 1977-04-12 American Home Products Corporation Benzylamine analgesics
US4366172A (en) * 1977-09-29 1982-12-28 The Upjohn Company 4-Amino-cyclohexanols, their pharmaceutical compositions and methods of use
IE913279A1 (en) * 1990-09-26 1992-04-08 Astra Ab (2-Thienyl)alkylamine Derivatives Having Neuroprotective¹Properties
DE19915601A1 (de) * 1999-04-07 2000-10-19 Gruenenthal Gmbh 3-Amino-3-arylpropan-1-ol-Derivate, deren Herstellung und Verwendung

Also Published As

Publication number Publication date
DE50104405D1 (de) 2004-12-09
AR029091A1 (es) 2003-06-04
NZ521439A (en) 2005-06-24
US20030181450A1 (en) 2003-09-25
EP1289514B1 (de) 2004-11-03
ATE281158T1 (de) 2004-11-15
DE10025238A1 (de) 2001-11-29
PE20011261A1 (es) 2002-01-26
US6784175B2 (en) 2004-08-31
AU7402201A (en) 2001-12-03
AU2001274022B2 (en) 2004-10-14
JP2004509842A (ja) 2004-04-02
MXPA02011410A (es) 2003-06-06
PT1289514E (pt) 2005-02-28
CA2406198A1 (en) 2002-10-16
EP1289514A1 (de) 2003-03-12
ES2231502T3 (es) 2005-05-16
WO2001089505A1 (de) 2001-11-29
HUP0301884A2 (hu) 2003-09-29

Similar Documents

Publication Publication Date Title
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
AR021981A1 (es) Composicion farmaceutica para una administracion por via oral destinada a evitar la desviacion de uso en detrimento de un tercero
BRPI0414539B8 (pt) composto, composição farmacêutica, e, uso de um composto
BR0317715A (pt) Composições e processos de uso de collajolie
TR199901077A2 (en) �spen�iyari form�lasyonlar.
UY28348A1 (es) Compuestos novedosos
PT1109812E (pt) Pirrolobenzodiazepinas
AR077414A2 (es) Compuestos de piperazina como antagonistas de taquinina sus sales y solvatos composiciones farmaceuticas que lo contienen su uso y procesos para su preparacion
HN2003000054A (es) Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo (cetpi), a procedimientos de uso y a procedimientos de preparacion de las mismas.
DOP2002000433A (es) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituidas y su uso
CY1107634T1 (el) Φαρμακευτικη συνθεση
HN2002000198A (es) Composiciones farmaceuticas de amlodipina y atorvastatina
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
UY27852A1 (es) Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
CR9391A (es) Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
HN2001000235A (es) Derivados puentes de piperazina
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
UY26718A1 (es) Uso de compuestos de 1-amino-5-fenilpentano-3-ol y/o 1-amino-6-fenilhexano-3-ol para la preparación de un medicamento con efecto antagonista de n-metil-d-aspartato- (nmda)
ECSP034532A (es) Derivados del 1-aminobutan-3-ol sustituido
PA8495001A1 (es) Nuevas formas cristalinas de un antibiotico macrolido.
DK1406888T3 (da) Substituerede gamma-lactonforbindelser som NMDA-antagonister
UY27620A1 (es) Ambroxoll para el tratamiento de dolores crónicos
HN2001000021A (es) Nuevos derivados de amidas heterociclicas
AR021616A1 (es) Cicloheptenos sustituidos, procedimiento para su preparacion y uso de los mismos.
AR046718A1 (es) Compuestos de benzazepina y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20131001